Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Direct-to-Tumor chemo blast halt advanced lung cancer?

NCT ID NCT07738367

Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This phase II trial is testing a procedure called bronchial artery chemoembolization (BACE) combined with systemic anti-cancer drugs in people with advanced non-small cell lung cancer who have no standard treatment options left. BACE delivers chemotherapy directly to the blood vessels feeding the tumor and then blocks them, aiming to increase drug exposure and cut off the tumor's blood supply. The study will see if this combination can control tumor growth in the chest and how safe it is, while also exploring effects on the immune system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bronchial artery chemoembolization (BACE) combined with systemic anti-tumor medications (chemotherapy, immune checkpoint inhibitors, or targeted agents)
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies, potentially helping to control tumors in the chest and improve outcomes.
What could go wrong
This is a small, early-phase study, so results may not apply to everyone. The combination therapy could cause side effects, and it is not yet known if it will be more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2. 2. Histopathologically confirmed advanced non-small cell lung cancer (NSCLC), with at least one measurable target lesion defined by RECIST Version 1.1. 3. Two eligible patient subgroups: Patients with negative driver gene alterations: experienced disease progression or intolerable toxicity after platinum-based doublet chemotherapy combined with PD-1/PD-L1 immune checkpoint inhibitors; Patients with positive driver gene mutations (e.g., EGFR, ALK): experienced disease progression or unacceptable adverse reactions after corresponding targeted therapy plus at least one line of systemic chemotherapy. 4. Target lung lesions are suitable for bronchial arterial chemoembolization (BACE), as assessed by interventional radiology specialists. 5. Adequate function of major vital organs. 6. Able to provide written informed consent prior to any study-related procedures. Exclusion Criteria: 1. Histopathological confirmation of mixed small cell lung cancer components. 2. Active bleeding or coagulation disorders. 3. Severe hypersensitivity to contrast media, chemotherapeutic agents, or combined study medications. 4. Extensive and rapidly progressive intra-pulmonary or extra-pulmonary metastatic lesions. 5. Angiography during the procedure shows that superselective catheterization cannot completely avoid hazardous blood vessels such as spinal arteries. 6. Severe pre-existing hepatic, renal, cardiac, or pulmonary dysfunction. 7. Estimated survival time less than 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.